Analysis of Short-term (Operating) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
UnitedHealth Group Inc., short-term (operating) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The operational activity ratios demonstrate a consistent pattern of liquidity management, characterized by efficient receivables collection and a gradual acceleration in the settlement of payables over the observed period from March 2022 through March 2026.
- Receivables Management
- Receivables turnover exhibits cyclical fluctuations, generally ranging between 13.80 and 19.43. A recurring seasonal pattern is evident, where the average receivable collection period peaks during the first quarter of each year, reaching 26 days in March 2024 and 24 days in March 2025. Conversely, collection efficiency improves significantly by the third quarter, with the collection period frequently dropping to 19 days, as seen in June 2023, September 2024, and September 2025.
- Payables Management
- Payables turnover shows a steady upward trend, increasing from 6.78 in March 2022 to 7.92 by March 2026. This indicates a gradual increase in the frequency with which obligations to suppliers are settled. Correspondingly, the average payables payment period has contracted from a high of 54 days in March 2022 to 46 days by the end of the analysis period. This consistent decline suggests a shift toward shorter payment cycles or more stringent credit terms from vendors.
- Operating Cycle Dynamics
- A significant gap is maintained between the collection of receivables and the payment of payables. While receivables are typically collected within 19 to 26 days, payables are settled over a longer duration of 46 to 54 days. This disparity indicates a favorable cash flow position, where cash is recovered from customers substantially faster than it is disbursed to creditors, providing a structural liquidity advantage in short-term operations.
AI Ask an analyst for more
Turnover Ratios
Average No. Days
Receivables Turnover
UnitedHealth Group Inc., receivables turnover calculation (quarterly data)
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Revenues, customers | 110,590) | 112,568) | 112,029) | 110,508) | 108,542) | 99,256) | 99,177) | 97,858) | 98,785) | 93,248) | 91,364) | 91,788) | 91,133) | 81,932) | 80,381) | 80,037) | 79,782) | ||||||
| Accounts receivable, net | 26,587) | 23,018) | 22,672) | 24,142) | 26,936) | 22,365) | 20,024) | 23,115) | 27,197) | 21,276) | 20,673) | 17,952) | 22,414) | 17,681) | 17,047) | 18,718) | 18,871) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Receivables turnover1 | 16.76 | 19.27 | 18.98 | 17.29 | 15.03 | 17.66 | 19.43 | 16.49 | 13.80 | 17.27 | 17.23 | 19.23 | 14.88 | 18.22 | 18.37 | 16.27 | 15.65 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | 5.50 | 5.59 | 5.39 | 5.41 | 5.78 | 6.06 | 5.85 | 5.94 | 6.11 | 6.11 | 6.15 | 6.52 | 6.89 | 7.02 | 7.03 | 6.33 | 6.20 | ||||||
| Elevance Health Inc. | 14.30 | 16.34 | 16.80 | 14.83 | 14.42 | 18.00 | 19.84 | 17.60 | 15.98 | 18.08 | 17.93 | 18.82 | 16.53 | 18.81 | 19.51 | 18.80 | 16.67 | ||||||
| Intuitive Surgical Inc. | 6.63 | 6.59 | 7.63 | 7.21 | 7.13 | 6.82 | 6.82 | 6.83 | 6.49 | 6.30 | 7.12 | 7.37 | 6.95 | 6.60 | 7.20 | 7.11 | 6.52 | ||||||
| Medtronic PLC | 5.46 | 5.15 | 5.43 | 5.27 | 5.42 | 5.28 | 5.42 | 5.39 | 5.44 | 5.21 | 5.23 | 5.48 | 5.85 | 5.71 | 5.84 | 5.79 | 5.82 | ||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Receivables turnover
= (Revenues, customersQ1 2026
+ Revenues, customersQ4 2025
+ Revenues, customersQ3 2025
+ Revenues, customersQ2 2025)
÷ Accounts receivable, net
= (110,590 + 112,568 + 112,029 + 110,508)
÷ 26,587 = 16.76
2 Click competitor name to see calculations.
A sustained growth trajectory in customer revenues is evident, increasing from 79,782 million USD in March 2022 to 110,590 million USD by March 2026. Despite this consistent expansion in top-line performance, the efficiency of receivable collections demonstrates significant quarterly volatility, characterized by cyclical fluctuations rather than a linear trend.
- Revenue and Receivables Correlation
- Customer revenues exhibited a steady upward trend over the analyzed period. However, net accounts receivable did not grow proportionally, instead showing a pattern of periodic surges. Notable peaks in receivables occurred in March 2023, March 2024, and March 2026, suggesting seasonal accumulations of outstanding balances that subsequently diminish in later quarters.
- Receivables Turnover Volatility
- The receivables turnover ratio fluctuated between a low of 13.80 in March 2024 and a high of 19.43 in September 2024. A recurring pattern is observable where turnover ratios tend to decline in the first quarter of the year and recover during the second and third quarters. This suggests a systematic delay in collections or a surge in credit sales at the close of the fiscal year, followed by aggressive collection activity in the subsequent quarters.
- Efficiency Analysis
- The period between September 2024 and December 2025 showed a general improvement in collection efficiency, with the ratio remaining predominantly above 17.00. The sharp decline to 13.80 in March 2024 represents the period of lowest operational efficiency regarding receivable conversion, coinciding with the highest recorded balance of net accounts receivable (27,197 million USD) up to that point. The final recording in March 2026 indicates a return to this cyclical dip, with the turnover ratio falling to 16.76 as receivables rose to 26,587 million USD.
AI Ask an analyst for more
Payables Turnover
UnitedHealth Group Inc., payables turnover calculation (quarterly data)
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Medical costs | 73,489) | 82,041) | 79,958) | 78,585) | 73,411) | 67,035) | 65,957) | 65,458) | 65,735) | 62,231) | 59,550) | 60,268) | 59,845) | 53,591) | 52,635) | 52,093) | 52,523) | ||||||
| Medical costs payable | 39,659) | 39,337) | 40,181) | 38,427) | 37,136) | 34,224) | 33,951) | 32,547) | 34,032) | 32,395) | 32,792) | 31,947) | 31,809) | 29,056) | 29,064) | 28,978) | 28,676) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Payables turnover1 | 7.92 | 7.98 | 7.44 | 7.42 | 7.32 | 7.72 | 7.64 | 7.77 | 7.28 | 7.47 | 7.11 | 7.08 | 6.86 | 7.26 | 7.07 | 6.90 | 6.78 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | 4.22 | 4.56 | 4.69 | 4.40 | 4.44 | 4.46 | 4.54 | 4.42 | 4.33 | 4.19 | 4.55 | 4.28 | 4.44 | 4.15 | 4.67 | 4.25 | 4.02 | ||||||
| Elevance Health Inc. | 8.06 | 8.68 | 8.38 | 8.07 | 7.87 | 8.10 | 8.17 | 8.09 | 7.54 | 7.72 | 7.61 | 7.54 | 7.57 | 7.47 | 7.48 | 7.35 | 7.28 | ||||||
| Intuitive Surgical Inc. | 10.71 | 13.42 | 11.10 | 11.44 | 10.39 | 14.05 | 11.88 | 12.91 | 12.64 | 12.69 | 11.66 | 11.10 | 12.99 | 13.78 | 12.01 | 12.68 | 14.36 | ||||||
| Medtronic PLC | 4.65 | 4.75 | 5.04 | 4.85 | 4.95 | 4.65 | 5.60 | 5.09 | 4.84 | 4.03 | 4.68 | 4.60 | 4.62 | 4.46 | 5.14 | 5.41 | 5.67 | ||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Payables turnover
= (Medical costsQ1 2026
+ Medical costsQ4 2025
+ Medical costsQ3 2025
+ Medical costsQ2 2025)
÷ Medical costs payable
= (73,489 + 82,041 + 79,958 + 78,585)
÷ 39,659 = 7.92
2 Click competitor name to see calculations.
An examination of the operating activity ratios reveals a consistent increase in both absolute medical costs and the efficiency of payable settlements over the period from March 2022 to March 2026.
- Medical Costs and Payables Volume
- Medical costs exhibited a sustained upward trajectory, rising from 52,523 million USD in March 2022 to a peak of 82,041 million USD in December 2025. Correspondingly, medical costs payable grew from 28,676 million USD to 39,659 million USD over the same timeframe. This parallel growth indicates a significant scaling of healthcare operations and a proportional increase in the volume of obligations to providers.
- Payables Turnover Ratio Trends
- The payables turnover ratio demonstrates a general upward trend, indicating a more rapid settlement of medical liabilities. The ratio started at 6.78 in March 2022 and reached a peak of 7.98 in December 2025. Despite a temporary contraction to 6.86 in March 2023, the ratio recovered and maintained a higher baseline, ending the period at 7.92 in March 2026.
- Operational Efficiency Insights
- The increase in the turnover ratio, occurring alongside rising absolute costs, suggests an improvement in the frequency of payments to providers. The transition from 6.78 to 7.92 indicates that the organization is clearing its medical payables more quickly than in previous years, which may reflect enhanced cash flow management or shifts in contractual payment terms with medical vendors.
AI Ask an analyst for more
Working Capital Turnover
UnitedHealth Group Inc., working capital turnover calculation (quarterly data)
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Current assets | 91,127) | 90,582) | 95,067) | 93,699) | 96,285) | 85,779) | 92,258) | 92,038) | 88,942) | 78,437) | 91,905) | 89,869) | 93,895) | 69,069) | 82,937) | 68,356) | 69,029) | ||||||
| Less: Current liabilities | 114,124) | 114,897) | 115,526) | 110,781) | 113,471) | 103,769) | 101,565) | 104,670) | 104,431) | 99,054) | 114,179) | 112,981) | 116,482) | 89,237) | 100,935) | 88,698) | 88,170) | ||||||
| Working capital | (22,997) | (24,315) | (20,459) | (17,082) | (17,186) | (17,990) | (9,307) | (12,632) | (15,489) | (20,617) | (22,274) | (23,112) | (22,587) | (20,168) | (17,998) | (20,342) | (19,141) | ||||||
| Revenues, customers | 110,590) | 112,568) | 112,029) | 110,508) | 108,542) | 99,256) | 99,177) | 97,858) | 98,785) | 93,248) | 91,364) | 91,788) | 91,133) | 81,932) | 80,381) | 80,037) | 79,782) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Working capital turnover1 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Benchmarks | |||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | 6.33 | 4.67 | 4.27 | 3.91 | 4.17 | 4.42 | 4.63 | 4.35 | 4.83 | 4.54 | 4.15 | 4.39 | 4.21 | 4.48 | 3.92 | 3.63 | 4.13 | ||||||
| Elevance Health Inc. | 7.59 | 7.50 | 7.00 | 7.96 | 8.11 | 7.85 | 6.87 | 6.92 | 8.59 | 7.83 | 7.92 | 7.69 | 7.60 | 8.37 | 9.11 | 8.85 | 8.65 | ||||||
| Intuitive Surgical Inc. | 1.53 | 1.29 | 1.43 | 1.30 | 1.42 | 1.56 | 1.42 | 1.23 | 1.17 | 1.14 | 0.95 | 1.03 | 1.15 | 1.29 | 1.21 | 1.17 | 1.26 | ||||||
| Medtronic PLC | 2.92 | 3.07 | 3.11 | 3.22 | 2.79 | 2.90 | 2.54 | 2.57 | 2.46 | 2.47 | 2.81 | 2.82 | 3.84 | 2.97 | 2.21 | 2.13 | 2.15 | ||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Working capital turnover
= (Revenues, customersQ1 2026
+ Revenues, customersQ4 2025
+ Revenues, customersQ3 2025
+ Revenues, customersQ2 2025)
÷ Working capital
= (110,590 + 112,568 + 112,029 + 110,508)
÷ -22,997 = —
2 Click competitor name to see calculations.
An analysis of the operating activity ratios reveals a persistent negative working capital position coupled with consistent revenue growth over the observed period from March 2022 to March 2026.
- Working Capital Trends
- The working capital remained consistently negative throughout the entire period, indicating that current liabilities exceeded current assets in every reported quarter. A notable period of relative improvement occurred during 2024, where the deficit narrowed from -15,489 million in March to a peak of -9,307 million in September. This trend reversed in the latter half of 2024 and through 2025, with the deficit widening to a period low of -24,315 million in September 2025 before slightly recovering to -22,997 million by March 2026.
- Revenue Trajectory
- Customer revenues exhibited a steady and sustained upward trajectory. Revenues increased from 79,782 million in March 2022 to 110,590 million by March 2026. This consistent growth reflects an expansion in operational scale and a continuous increase in top-line performance over the four-year window.
- Working Capital Turnover Dynamics
- Because working capital remained negative, the working capital turnover ratio is negative across all periods. This suggests an operational model where current liabilities are utilized to fund the growth of revenues. The relationship between the expanding revenue base and the fluctuating negative working capital indicates a high level of reliance on short-term financing or deferred obligations to support increasing business volume. The most significant contraction of the working capital deficit in mid-2024 coincided with a period of steady revenue growth, suggesting a temporary shift in liquidity management before returning to a more aggressive negative working capital posture in 2025.
AI Ask an analyst for more
Average Receivable Collection Period
UnitedHealth Group Inc., average receivable collection period calculation (quarterly data)
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Receivables turnover | 16.76 | 19.27 | 18.98 | 17.29 | 15.03 | 17.66 | 19.43 | 16.49 | 13.80 | 17.27 | 17.23 | 19.23 | 14.88 | 18.22 | 18.37 | 16.27 | 15.65 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||
| Average receivable collection period1 | 22 | 19 | 19 | 21 | 24 | 21 | 19 | 22 | 26 | 21 | 21 | 19 | 25 | 20 | 20 | 22 | 23 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | 66 | 65 | 68 | 67 | 63 | 60 | 62 | 61 | 60 | 60 | 59 | 56 | 53 | 52 | 52 | 58 | 59 | ||||||
| Elevance Health Inc. | 26 | 22 | 22 | 25 | 25 | 20 | 18 | 21 | 23 | 20 | 20 | 19 | 22 | 19 | 19 | 19 | 22 | ||||||
| Intuitive Surgical Inc. | 55 | 55 | 48 | 51 | 51 | 54 | 53 | 53 | 56 | 58 | 51 | 50 | 53 | 55 | 51 | 51 | 56 | ||||||
| Medtronic PLC | 67 | 71 | 67 | 69 | 67 | 69 | 67 | 68 | 67 | 70 | 70 | 67 | 62 | 64 | 63 | 63 | 63 | ||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 16.76 = 22
2 Click competitor name to see calculations.
The efficiency of receivables management exhibits a cyclical pattern characterized by moderate fluctuations in both turnover rates and collection timelines. Over the analyzed period, the ability to convert receivables into cash remained relatively stable, with the collection window generally fluctuating between 19 and 26 days.
- Receivables Turnover Trends
- The turnover ratio experienced variability, reaching a minimum of 13.80 in March 2024 and a peak of 19.43 in June 2024. Despite these fluctuations, the ratio predominantly remained within a range of 15.0 to 19.0, suggesting a consistent operational capacity to recover credit sales over the long term.
- Average Receivable Collection Period
- A recurring seasonal trend is observable, where the collection period typically expands during the first quarter of each year. This is evidenced by peaks of 25 days in March 2023, 26 days in March 2024, and 24 days in March 2025. These quarterly increases are consistently offset by a contraction in the collection window during the middle and latter portions of the year, frequently returning to a baseline of 19 to 21 days.
- Correlation Between Turnover and Collection Velocity
- A strict inverse correlation exists between the turnover ratio and the average collection period. The periods of maximum operational efficiency, marked by a 19-day collection cycle, coincide with the highest turnover ratios, such as the 19.43 ratio in June 2024 and the 19.27 ratio in December 2025. Conversely, the lowest turnover ratios align with the expanded collection periods seen every March.
AI Ask an analyst for more
Average Payables Payment Period
UnitedHealth Group Inc., average payables payment period calculation (quarterly data)
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Payables turnover | 7.92 | 7.98 | 7.44 | 7.42 | 7.32 | 7.72 | 7.64 | 7.77 | 7.28 | 7.47 | 7.11 | 7.08 | 6.86 | 7.26 | 7.07 | 6.90 | 6.78 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||
| Average payables payment period1 | 46 | 46 | 49 | 49 | 50 | 47 | 48 | 47 | 50 | 49 | 51 | 52 | 53 | 50 | 52 | 53 | 54 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | 87 | 80 | 78 | 83 | 82 | 82 | 80 | 83 | 84 | 87 | 80 | 85 | 82 | 88 | 78 | 86 | 91 | ||||||
| Elevance Health Inc. | 45 | 42 | 44 | 45 | 46 | 45 | 45 | 45 | 48 | 47 | 48 | 48 | 48 | 49 | 49 | 50 | 50 | ||||||
| Intuitive Surgical Inc. | 34 | 27 | 33 | 32 | 35 | 26 | 31 | 28 | 29 | 29 | 31 | 33 | 28 | 26 | 30 | 29 | 25 | ||||||
| Medtronic PLC | 79 | 77 | 72 | 75 | 74 | 78 | 65 | 72 | 75 | 91 | 78 | 79 | 79 | 82 | 71 | 67 | 64 | ||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 7.92 = 46
2 Click competitor name to see calculations.
An analysis of the quarterly operating activity ratios reveals a consistent trend toward accelerated payment of obligations to suppliers. There is a clear inverse correlation between the payables turnover ratio and the average payables payment period over the observed timeframe from March 2022 through March 2026.
- Payables Turnover Trends
- The payables turnover ratio exhibited a general upward trajectory, increasing from 6.78 in March 2022 to 7.92 by March 2026. While a brief contraction occurred in March 2023, where the ratio dipped to 6.86, the subsequent trend remained positive. A notable period of acceleration was observed between December 2023 and June 2024, with the ratio rising from 7.47 to 7.77, eventually peaking at 7.98 in December 2025.
- Average Payables Payment Period
- The average time taken to settle payables decreased from 54 days in March 2022 to 46 days by March 2026. The payment cycle showed moderate volatility in the first year, peaking again at 53 days in March 2023 before entering a steady decline. The most significant reductions occurred throughout 2024, where the period dropped from 50 days in March to 47 days by December. The final quarters of the period demonstrate stabilization, with the payment duration holding steady between 46 and 49 days.
- Operational Implications
- The increase in turnover combined with the reduction in the payment period indicates a more aggressive approach to managing short-term liabilities. The transition from a 54-day cycle to a 46-day cycle suggests improved liquidity or a strategic shift toward faster settlement of supplier invoices, which typically reflects stronger cash flow positioning or a desire to optimize supplier relationships.
AI Ask an analyst for more